CN121021680A - 抗hiv抗体10-1074变体 - Google Patents

抗hiv抗体10-1074变体

Info

Publication number
CN121021680A
CN121021680A CN202511190725.6A CN202511190725A CN121021680A CN 121021680 A CN121021680 A CN 121021680A CN 202511190725 A CN202511190725 A CN 202511190725A CN 121021680 A CN121021680 A CN 121021680A
Authority
CN
China
Prior art keywords
seq
antibody
hiv
antigen
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511190725.6A
Other languages
English (en)
Chinese (zh)
Inventor
米歇尔·努森兹韦格
R·R·凯特切姆
C·C·西斯卡
A·J·吉莱斯皮
R·H·克拉克
B·A·克尔温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of CN121021680A publication Critical patent/CN121021680A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202511190725.6A 2018-09-14 2019-09-12 抗hiv抗体10-1074变体 Pending CN121021680A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862731356P 2018-09-14 2018-09-14
US62/731,356 2018-09-14
CN201980074145.7A CN113271974B (zh) 2018-09-14 2019-09-12 抗hiv抗体10-1074变体
PCT/US2019/050823 WO2020056145A1 (en) 2018-09-14 2019-09-12 Anti-hiv antibody 10-1074 variants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980074145.7A Division CN113271974B (zh) 2018-09-14 2019-09-12 抗hiv抗体10-1074变体

Publications (1)

Publication Number Publication Date
CN121021680A true CN121021680A (zh) 2025-11-28

Family

ID=69778483

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511190725.6A Pending CN121021680A (zh) 2018-09-14 2019-09-12 抗hiv抗体10-1074变体
CN201980074145.7A Active CN113271974B (zh) 2018-09-14 2019-09-12 抗hiv抗体10-1074变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980074145.7A Active CN113271974B (zh) 2018-09-14 2019-09-12 抗hiv抗体10-1074变体

Country Status (8)

Country Link
US (2) US12441782B2 (https=)
EP (1) EP3849612A4 (https=)
JP (1) JP2022500042A (https=)
KR (1) KR102938690B1 (https=)
CN (2) CN121021680A (https=)
AU (1) AU2019338454A1 (https=)
CA (1) CA3112486A1 (https=)
WO (1) WO2020056145A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
US12195524B2 (en) 2020-08-25 2025-01-14 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
WO2023154761A2 (en) * 2022-02-08 2023-08-17 The Wistar Institute Of Anatomy And Biology Modified primary immune cells for induction or enhancement of immunotherapy
KR20250051732A (ko) * 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81A (en) 1836-11-15 Erawijjg
US6593A (en) 1849-07-17 Cutting
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
CA3249351A1 (en) * 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Neutralizing antibodies against human immunodeficiency viruses (HIV)
EA032929B1 (ru) * 2011-05-17 2019-08-30 Дзе Рокфеллер Юниверсити Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
WO2013192589A1 (en) * 2012-06-21 2013-12-27 California Institute Of Technology Antibodies targeting hiv escape mutants
LT2908912T (lt) * 2012-10-18 2020-09-25 The Rockefeller University Plačiai neutralizuojantys anti-živ antikūnai
US10676521B2 (en) * 2014-07-21 2020-06-09 The Rockefeller University Combination of broadly neutralizing HIV antibodies and viral inducers
MX2019007738A (es) * 2016-12-27 2019-09-05 Univ Rockefeller Anticuerpos contra el vih ampliamente neutralizantes y métodos de uso de ellos.
WO2020086782A1 (en) * 2018-10-24 2020-04-30 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hiv

Also Published As

Publication number Publication date
CN113271974A (zh) 2021-08-17
CN113271974B (zh) 2025-09-09
EP3849612A1 (en) 2021-07-21
JP2022500042A (ja) 2022-01-04
KR20210060548A (ko) 2021-05-26
AU2019338454A1 (en) 2021-04-08
US20220119504A1 (en) 2022-04-21
US12441782B2 (en) 2025-10-14
KR102938690B1 (ko) 2026-03-13
CA3112486A1 (en) 2020-03-19
EP3849612A4 (en) 2022-07-06
WO2020056145A1 (en) 2020-03-19
US20260049122A1 (en) 2026-02-19

Similar Documents

Publication Publication Date Title
US20260049122A1 (en) Anti-HIV Antibody 10-1074 Variants
JP7759067B2 (ja) 広域中和抗ｈｉｖ－１抗体およびその使用方法
TWI735491B (zh) 人類免疫不全病毒中和抗體
CN112225798B (zh) 人类免疫缺陷病毒中和抗体及其使用方法
CN112920269B (zh) 广泛中和性抗hiv抗体
US20250066457A1 (en) Antibodies targeting hiv escape mutants
WO2021207152A1 (en) Cross-reactive coronavirus antibodies and uses thereof
CN106565840B (zh) 抗乙肝表面抗原的抗体及其用途
CN114641488B (zh) 具有降低的多反应性的抗hiv疫苗抗体
WO2024053719A1 (ja) コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
US20230322906A1 (en) Hiv-1 specific antibodies and uses thereof
HK40103004A (zh) 广谱中和抗hiv-1抗体及其使用方法
HK40051031A (en) Anti-hiv antibody 10-1074 variants
JP2026508140A (ja) 帯状疱疹の治療
CN120518755A (zh) 一种具有adcc效应的抗hiv广谱中和抗体及其应用
HK40041858B (en) Human immunodeficiency virus neutralizing antibodies and methods of use thereof
HK40067703A (en) Anti-hiv vaccine antibodies with reduced polyreactivity
HK40019070B (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof
HK40019070A (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof
EA042959B1 (ru) Нейтрализирующие анти-вич-1 антитела широкого спектра действия и способы их применения
IL300355A (en) Broadly neutralizing antibodies against HIV, their methods and uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination